Navigation Links
Foundation Venture Capital Group Invests in Company Developing Plaque-Reducing Dental Hygiene Products
Date:6/17/2011

NEW BRUNSWICK, N.J., June 17, 2011 /PRNewswire-USNewswire/ -- Affineti Biologics has received a commitment of up to $500,000 from Foundation Venture Capital Group (FVCG) to advance its research in the development of therapeutic and diagnostic products based on new discoveries in oral biology and dental medicine.

According to James M. Golubieski, president of FVCG, the company invested in Affineti because positive results from studies for anti-caries and periodontal therapy look promising in their ability to affect plaque reduction, influencing dental hygiene and systemic medicine.

Affineti founder Dr. Daniel Fine, also a professor and chair, Department of Oral Biology at UMDNJ-New Jersey Dental School, believes the development of products based on his research will prove more effective than others currently available.

His group uses biological principals to create hybrid or fusion proteins that adhere to tissues with potent but non-toxic antimicrobial effects.  He hopes to use these proteins to deliver effective substances locally, avoiding systemic complications. In the short term, Dr. Fine plans to use these proteins in conditions related to the oral cavity and then expand to include mucosal infections in other sites throughout the body.

"We are focused on anti-caries, periodontal disease therapy and dry mouth treatment," Dr. Fine explained. "Additional testing for yeast and bacterial overgrowth will allow us to bring our product for an effective mouthwash for anti-caries, periodontitis and dry mouth to clinical trials shortly."

In addition to the adverse effect of plaque on dental health, current research supports the idea that dental plaque buildup also increases the risk of cardiovascular disease and stroke.

"The link between gum disease and cardiovascular disease is strong enough for us to consider that Dr. Fine's research will impact health on many levels," said Dr. George F. Heinrich, vice chair and CEO of Foundation Venture Capital Group. "We look forward to helping him reach the clinical trial level."

For more information, contact James M. Golubieski, president of FVCG, at (908) 731-6601 or at jgolubieski@njhf.org.

About Foundation Venture Capital Group

Foundation Venture Capital Group, an affiliate of New Jersey Health Foundation, was founded in 2006 to invest in commercially viable new start-up companies developing technology by faculty at the University of Medicine and Dentistry of New Jersey. In addition to Affineti, it has invested in:  

  • Actinobac Biomed Inc., developing a therapeutic agent targeting blood cells for the treatment of hematological malignancies;
  • CellXplore, Inc., engaged in the development of biomarker-based in vitro diagnostic assays for cancer;
  • Celvive, Inc., working to develop technology to treat patients with chronic spinal cord injuries with their own adult stem cells;
  • Durin Technologies, working to develop a blood test to diagnose Alzheimer's disease;
  • Longevica Pharmaceuticals, Inc., developing a chemoprotective agent that may keep normal cells healthy during cancer treatments (FVCG's equity interest in Longevica was recently sold to Rostock International, LTD, a subsidiary of a Moscow (Russia) based global investment firm);
  • Snowdon Pharmaceuticals, a drug discovery company focused on several major therapeutic areas.


'/>"/>
SOURCE Foundation Venture Capital Group, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transgenomic, Inc. Launches Best-in-Class Next-Generation Sequencing Test for Nuclear Mitochondrial Disorders at the 2011 United Mitochondrial Disease Foundation Meeting
2. Patient Advocate Foundation Announces Additional Support for Patient Co-Pay Relief Program Serving Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Patients
3. Brin Wojcicki Foundation Announces $50-Million Challenge Grant to Michael J. Fox Foundation to Spur Progress Toward Parkinsons Cure
4. SyntheZyme Wins Second National Science Foundation Grant to Commercialize Promising Biopesticide
5. Boston Scientific Supports Asthma Awareness Month With Donation to Asthma Foundation
6. Bill & Melinda Gates Foundation Funds Bold Ideas Including Empty Virus Shells to Improve Polio Immunity, Dirt-Charged Cell Phones, and Fertilizer Pellets that Reduce Health Risks
7. Kanzius Cancer Research Foundation Earns $1 for Each New Facebook Fan
8. Fueling Interventional Radiology Growth: SIR Foundation Announces Navilyst Medical Pledge
9. Newborn Possibilities Fund Awards Grant to Georgia Health Sciences University Foundation to Support Groundbreaking Pediatric Research
10. Yuma Therapeutics Awarded a Research Grant by the Alzheimers Drug Discovery Foundation to Develop Novel Therapeutics for Alzheimers Disease
11. FXB Center Partners With The Merck Company Foundation to Reduce Mother-to-Child HIV Transmission Rates in Botswana
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):